Phapros Posts 311.58% Rise in Net Profit in Third Quarter of 2026
Jakarta (ANTARA) – PT Phapros Tbk (Phapros/PEHA), a subsidiary of PT Kimia Farma Tbk, recorded consolidated net profit of Rp31.60 billion in the third quarter, or over January–September 2026, up 311.58% year on year amid sales growth and improved profit margins.
Phapros President Director Intan Abdams Katoppo said the improvement in profitability was reflected in its earnings before interest, tax, depreciation and amortisation (EBITDA) margin, which rose to 15% from 13.2%.
“The increase in the EBITDA margin shows that we are becoming more efficient in our operations,” Intan said in an official statement received in Jakarta on Monday.
According to the unaudited interim consolidated financial statements, Phapros’ sales grew 15.07% to Rp786.57 billion, from Rp683.58 billion in January–September 2025.
The company’s EBITDA increased 30.26% to Rp117.66 billion compared with the same period a year earlier.
By sales segment, generic medicines bearing the official generic logo made the largest contribution to revenue, at Rp423.20 billion, up from Rp358.03 billion in January–September 2025.
Sales growth was accompanied by an 11.04% rise in cost of goods sold (COGS) to Rp384.04 billion, from Rp345.86 billion.
As COGS rose more slowly than sales, the COGS-to-sales ratio fell to 48.8% from 50.6%.
In line with this, gross profit increased 19.19% to Rp402.53 billion from Rp337.72 billion, while the gross margin rose to 51.2% from 49.4%.
Meanwhile, the company’s operating expenses increased 12.93% to Rp321.15 billion, compared with Rp284.37 billion in the same period a year earlier.
Despite the higher operating expenses, Phapros recorded operating profit of Rp80.97 billion, up 55.90% from Rp51.94 billion in January–September 2025.
The company also reported that finance costs fell to Rp34.27 billion from Rp38.03 billion in the same period a year earlier.
As a result, profit before tax rose 233.59% to Rp48.65 billion from Rp14.58 billion, while consolidated net profit increased from Rp7.68 billion to Rp31.60 billion.
Intan said the company’s improved performance was supported by several measures, including strengthening working capital, controlling costs, developing its product and business portfolios, and transforming its systems and business processes since 2025.
She said implementation of the strategy was regularly evaluated to sustain the company’s operational performance and profitability.
“We are optimistic that Phapros’ positive financial performance will continue through the end of this year,” she said.
In terms of cash flow, Phapros recorded net cash from operating activities of Rp129.96 billion, up 142.85% from Rp53.51 billion in January–September 2025.
Cash and cash equivalents stood at Rp157.54 billion as at 30 September 2026, up from Rp92.38 billion in the same period a year earlier.
The company’s total assets stood at Rp1.45 trillion at the end of September 2026, an increase of 4.74% from Rp1.39 trillion at the end of December 2025.
For comparison, Phapros recorded sales of Rp940.88 billion in 2025, an increase of 26.34% on the previous year.
During that period, the company posted consolidated net profit of Rp27.44 billion, after recording a loss of Rp290.63 billion in 2024.
Going forward, the company said it would continue to control costs, develop its product portfolio and improve operational reliability to support business performance.
Source: jawawa.id (https://jawawa.id/newsitem/phapros-posts-311-58-rise-in-net-profit-in-third-quarter-of-2026-1793620311)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5826863/phapros-catat-kenaikan-laba-bersih-31158-persen-pada-kuartal-iii-2026), translated from Indonesian